One of the foundations of D&P Medical Group is clinical research, with special attention to the fields of wound care, medical cannabis, and hyperbaric medicine. We have an extensive clinical research history and a partnership with Serena Group, one of the industry leaders in wound care, hyperbaric medicine, and clinical research. Through this partnership and our experience, we have a unique and powerful access to dedicated research centers and specialized patient populations. We also provide the opportunity for the research to be published and/or presented in the appropriate forums and on an international level. From single case studies to large, multi-center trials, D&P Medical Group can help your organization meet its research goals.
- 1/10/2020: After living with insomnia for 12 years, our Research Editor’s mom took part in a research study investigating the microbiome and sleep.
- 1/2/2020: Breakthrough research shows that type 2 diabetes occurs when fat from the liver overspills into the pancreas and confirms that weight loss can reverse it.
- 2/12/2020: A common variation in a human gene that affects the brain's reward processing circuit increases vulnerability to the rewarding effects of the main psychoactive ingredient of cannabis in adolescent females, but not males, according to preclinical research. As adolescence represents a highly sensitive period of brain development with the highest risk for initiating cannabis use, these findings in mice have important implications for understanding the influence of genetics on cannabis dependence in humans.
- 2/7/2020: Few cannabis consumers understand what the THC numbers on packages of cannabis edibles really mean, according to a new study. The study, which surveyed nearly 1,000 Canadians aged 16 to 30, found that most consumers could not identify whether a cannabis edible contained 'low' or 'high' levels of THC based on the label.
- 2/13/2020: A new 'smart bandage' could help improve clinical care for people with chronic wounds.
- 2/13/2020: A new study found that treating soft tissue sarcoma with radiation over a significantly shorter period of time is safe, and likely just as effective, as a much longer conventional course of treatment.